Biaxin
$ 107,00 – $ 427,00Price range: $ 107,00 through $ 427,00
Biltricide
$ 50,00
Biktarvy
$ 800,00
Biktarvy is a complete, once-daily single-tablet regimen used to treat HIV-1 infection in both adults and pediatric patients. This powerful medication combines three active ingredients–bictegravir, emtricitabine, and tenofovir alafenamide–into one convenient dose. It functions by inhibiting the virus’s ability to replicate, which effectively lowers the viral load and strengthens the immune system. The treatment is indicated for individuals who are new to HIV therapy or those looking to replace their current stable antiretroviral regimen. Consistent use of Biktarvy helps maintain viral suppression and supports the overall long-term health of those living with HIV-1.
SKU:
Biktarvy
Category: AntiVirals
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Biktarvy belongs to a group of antiretroviral medications known as complete single-tablet regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It combines an integrase strand transfer inhibitor (INSTI) with two nucleoside reverse transcriptase inhibitors (NRTIs) into a once-daily oral formulation. In the United States, this medication is available strictly by prescription (Rx) and must be administered under the active supervision of a licensed healthcare provider.
Treatment with Biktarvy does not cure HIV-1 infection or AIDS, but it effectively suppresses viral replication to lower the viral load in the blood to undetectable levels when taken consistently as prescribed. Maintaining an undetectable viral load preserves immune system function, reduces the incidence of opportunistic infections, and prevents HIV transmission to sexual partners.
| Attribute | Product Details |
|---|---|
| Active Ingredients | Bictegravir, Emtricitabine, Tenofovir Alafenamide |
| Therapeutic Class | Antiretroviral Combination (INSTI + NRTI) |
| Dosage Form | Oral Film-Coated Tablet |
| Route of Administration | Oral |
| Prescription Status | Prescription Only (Rx) |
| Primary Purpose | HIV-1 Infection Management |
| Dosing Frequency | Once Daily |
Main uses
Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 14 kg. It is approved both for individuals who have no prior antiretroviral treatment history and for replacing a current stable antiretroviral regimen in patients who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on their current therapy. To switch to Biktarvy, patients must have no history of treatment failure and no known viral resistance to bictegravir, emtricitabine, or tenofovir.
This formulation is not approved for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) to reduce the risk of acquiring HIV-1. Any use outside of established FDA-approved antiretroviral treatment regimens represents off-label use and should only occur under explicit clinical guidance from a qualified specialist.
How the drug works
Biktarvy contains three active antiretroviral agents that target distinct stages of the HIV-1 replication cycle. Bictegravir acts as an integrase strand transfer inhibitor (INSTI). It binds to the active site of the viral integrase enzyme, blocking the integration of HIV-1 proviral DNA into the host cell genome, which prevents viral replication.
Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs). Emtricitabine is a synthetic nucleoside analogue of cytidine, while tenofovir alafenamide is a targeted prodrug of tenofovir (an acyclic nucleoside phosphonate analogue of adenosine monophosphate). Both compounds undergo intracellular phosphorylation to active metabolites–emtricitabine triphosphate and tenofovir diphosphate, respectively. These active forms incorporate into the viral DNA strand via the HIV-1 reverse transcriptase enzyme, causing DNA chain termination and halting retroviral replication.
How it’s absorbed and eliminated
Following oral administration, bictegravir, emtricitabine, and tenofovir alafenamide are rapidly absorbed through the gastrointestinal tract. Bictegravir exhibits high plasma protein binding (greater than 99%) and is eliminated primarily through dual metabolic pathways involving cytochrome P450 3A4 (CYP3A4) and UDP-glucuronosyltransferase 1A1 (UGT1A1). The plasma elimination half-life of bictegravir is approximately 17.3 hours, allowing for once-daily dosing.
Tenofovir alafenamide is a prodrug designed to deliver tenofovir directly into peripheral blood mononuclear cells (PBMCs) at higher intracellular concentrations while maintaining lower systemic plasma levels than tenofovir disoproxil fumarate. Tenofovir alafenamide is metabolized intracellularly to active tenofovir diphosphate, which exhibits a prolonged intracellular half-life of approximately 150 to 180 hours. Emtricitabine is unbound to plasma proteins and is predominantly eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion, with a plasma half-life of approximately 10 hours.
Dosing schedule
The standard recommended dosage for adults and pediatric patients weighing at least 25 kg is one tablet containing 50 mg of bictegravir, 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide taken orally once daily. For pediatric patients weighing between 14 kg and less than 25 kg, a lower-strength tablet containing 30 mg of bictegravir, 120 mg of emtricitabine, and 15 mg of tenofovir alafenamide is prescribed.
Tablets should be swallowed whole with water and can be taken with or without food. In patients with an estimated creatinine clearance (CrCl) of 30 mL/min or greater, no dosage adjustment is required. Biktarvy is generally not recommended in patients with severe renal impairment (CrCl less than 30 mL/min) unless they are virologically suppressed on a stable regimen and receiving chronic hemodialysis.
Compatibility with other medicines
Co-administration of Biktarvy with certain medications can lead to significant pharmacokinetic drug interactions. Bictegravir binds to polyvalent cations; therefore, antacids containing aluminum, magnesium, or calcium, as well as mineral supplements containing iron or zinc, markedly reduce bictegravir absorption. Biktarvy should be taken at least 2 hours before or 6 hours after taking polyvalent cation-containing antacids or supplements. Alternatively, Biktarvy and calcium or iron supplements can be taken together with food.
Strong CYP3A and UGT1A1 inducers–such as rifampin, St. John’s wort, carbamazepine, oxcarbazepine, phenytoin, and phenobarbital–substantially lower plasma concentrations of bictegravir and tenofovir alafenamide, which can lead to loss of therapeutic effect and development of viral resistance. Co-administration with these drugs is contraindicated or not recommended. Additionally, Biktarvy is contraindicated with dofetilide due to the inhibition of renal organic cation transporters, which can increase plasma concentrations of dofetilide and elevate the risk of life-threatening cardiac arrhythmias.
Adverse reactions
The overall clinical safety profile of Biktarvy is well documented. The most common mild to moderate side effects reported in clinical trials include diarrhea, nausea, headache, fatigue, and abnormal or vivid dreams. Dizziness, flatulence, dyspepsia, and mild cutaneous rash may also occur in a smaller percentage of patients.
Laboratory abnormalities observed during treatment include mild, asymptomatic elevations in serum creatinine. Bictegravir inhibits the renal tubular secretion of creatinine without altering actual glomerular filtration rate (GFR). This rise in serum creatinine typically occurs within the first four weeks of initiating therapy and stabilizes thereafter. Asymptomatic elevations in serum bilirubin and creatine kinase have also been documented in routine laboratory monitoring.
Important precautions
Biktarvy carries a Boxed Warning regarding the risk of post-treatment acute exacerbation of hepatitis B virus (HBV). Patients must be screened for HBV infection prior to or when initiating antiretroviral therapy. Discontinuation of Biktarvy in patients co-infected with HIV-1 and HBV has been associated with severe acute exacerbations of hepatitis B due to the withdrawal of anti-HBV activity provided by emtricitabine and tenofovir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in co-infected patients who stop taking Biktarvy.
Immune Reconstitution Inflammatory Syndrome (IRIS) may develop in patients treated with combination antiretroviral therapy. During the initial phase of treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium, cytomegalovirus, Pneumocystis jirovecii pneumonia, or tuberculosis). Renal monitoring–including serum creatinine, estimated creatinine clearance, urine glucose, and urine protein–is recommended prior to starting and periodically during therapy.
Red flags
Patients should be aware of critical signs that necessitate immediate clinical assessment. If any severe reaction or unexpected decline in physical condition occurs, emergency medical evaluation is required.
| Red Flag Symptom | Potential Underlying Condition | Required Action |
|---|---|---|
| Swelling of face, lips, tongue, or severe skin rash | Hypersensitivity / Anaphylaxis | Seek emergency care immediately |
| Jaundice (yellowing of eyes/skin), dark urine, pale stools | Hepatic flare / Liver injury | Contact physician immediately |
| Rapid breathing, severe fatigue, unusual muscle pain | Lactic acidosis | Seek emergency medical evaluation |
| Unexplained high fever, severe swollen lymph nodes | Immune Reconstitution Syndrome | Contact medical provider promptly |
Food and alcohol interactions
Biktarvy can be ingested with or without food without impacting its systemic bio-availability. However, taking the tablet with food allows for simultaneous administration with routine calcium or iron supplements, as food mitigates the chelation interaction between bictegravir and polyvalent cations.
Moderate alcohol consumption does not directly alter the pharmacokinetic pathways of bictegravir, emtricitabine, or tenofovir alafenamide. Nevertheless, chronic heavy alcohol intake can increase the burden on hepatic function and impair medication adherence, which is vital for maintaining long-term viral suppression.
If you skip a dose
High adherence to antiretroviral therapy is mandatory to preserve viral suppression and prevent the emergence of drug-resistant HIV-1 strains. If a dose is missed, it should be taken as soon as it is remembered on the same day, provided it is not close to the scheduled time for the next dose.
If the next scheduled dose is due within a short window, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never take two doses simultaneously or double the prescribed dose to compensate for a missed tablet.
Storage and expiration
Biktarvy should be stored at controlled room temperature below 30°C (86°F). The tablets must remain in their original container with the child-resistant closure tightly secured to protect the product from ambient moisture. The container includes a desiccant canister that should not be removed or swallowed.
Medication that has passed its stated expiration date on the packaging should not be used, as chemical potency cannot be guaranteed. Keep all pharmaceutical products safely out of the reach and sight of children and pets.
Common questions
Does Biktarvy cause significant weight gain?
Clinical studies evaluating integrase strand transfer inhibitor (INSTI)-based regimens, including bictegravir, have demonstrated weight gain in some patients after initiating therapy. This weight gain can be part of a return-to-health effect following viral suppression or an drug-class effect associated with newer antiretroviral agents. Patients concerned about weight changes should discuss lifestyle adjustments and cardiovascular health monitoring with their healthcare team.
Can Biktarvy be taken alongside daily antacids or multivitamins?
Antacids containing aluminum, magnesium, or calcium, as well as oral iron and zinc supplements, interfere with the absorption of bictegravir. To avoid reduced efficacy, Biktarvy must be taken 2 hours before or 6 hours after antacids. Alternatively, if taking calcium or iron supplements, Biktarvy can be taken at the same time if consumed with a meal.
Is Biktarvy prescribed for HIV post-exposure prophylaxis (PEP)?
Biktarvy is approved by the US FDA specifically for the management and treatment of established HIV-1 infection. While some clinical guidelines may consider integrase-inhibitor-based regimens off-label in non-occupational or occupational PEP settings, Biktarvy is not formally indicated for PEP or PrEP. Standard specialized PEP regimens should be determined by an emergency healthcare professional.
What changes to kidney function tests can be expected on Biktarvy?
Bictegravir inhibits the renal tubular transporter OCT2 and MATE1, which decreases the tubular secretion of creatinine without damaging actual kidney filtration function. Consequently, serum creatinine levels often rise slightly during the first few weeks of therapy and then plateau. A physician will monitor kidney parameters, including urine protein and blood urea nitrogen, to distinguish benign serum creatinine changes from true renal impairment.
Can treatment with Biktarvy be stopped if HIV-1 becomes undetectable?
No. An undetectable viral load indicates that the medication is successfully controlling viral replication, but it does not mean the virus has been eradicated from the body. Discontinuing Biktarvy allows latent HIV-1 reserves to reactivate, causing viral load rebound, immune failure, and potential resistance to antiretroviral drugs. Treatment must be continued indefinitely as directed by a physician.
In accordance with FDA guidelines.
This text is for informational purposes only and does not constitute individual medical advice.
Additional information
| Dosage |
50mg+200mg+25mg |
|---|---|
| Package |
10 pills |
| Ενεργός Ουσία | , , |
Related products
Acivir Pills
$ 51,00 – $ 200,00Price range: $ 51,00 through $ 200,00
Active substance: Acyclovir
More Details
This product has multiple variants. The options may be chosen on the product page
Albendazole
$ 46,00 – $ 121,00Price range: $ 46,00 through $ 121,00
Active substance: Albendazole
More Details
This product has multiple variants. The options may be chosen on the product page
Ascorbic Acid
$ 58,00 – $ 69,00Price range: $ 58,00 through $ 69,00
Active substance: Ascorbic Acid
More Details
This product has multiple variants. The options may be chosen on the product page
Chloroquine
$ 41,00 – $ 402,00Price range: $ 41,00 through $ 402,00
Active substance: Chloroquine
More Details
This product has multiple variants. The options may be chosen on the product page
Medex
$ 41,00 – $ 144,00Price range: $ 41,00 through $ 144,00
Active substance: Coumadin
More Details
This product has multiple variants. The options may be chosen on the product page
Molnupiravir
$ 229,00 – $ 706,00Price range: $ 229,00 through $ 706,00
Active substance: Molnupiravir
More Details
This product has multiple variants. The options may be chosen on the product page
Symmetrel
$ 47,00 – $ 306,00Price range: $ 47,00 through $ 306,00
Active substance: Amantadine
More Details
This product has multiple variants. The options may be chosen on the product page
Tamiflu
$ 66,00 – $ 427,00Price range: $ 66,00 through $ 427,00
Active substance: Oseltamivir
More Details
This product has multiple variants. The options may be chosen on the product page
